Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD22 CAR-T for B-cell Malignancies
NCT02794961Phase 2Unknown
- Start
- Jun 2016
- Primary completion
- Jun 2018
- Countries
- 1
01
Overview
Phase 2, open-label trial of anti-CD22 chimeric antigen receptor T cells in B-cell hematological malignancy (BHM). Primary endpoint: Complete Remission Rate at 12 months. Status: unknown.
02
Drugs
anti-CD22 chimeric antigen receptor T cells
03
Conditions
B-cell hematological malignancy (BHM)
Beyond the preview
Go deeper on NCT02794961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02794961.